Minerva Neurosciences reports $2.7 mln Q3 net loss

Reuters11-05

<a href="https://laohu8.com/S/NERV">Minerva Neurosciences</a> reports $2.7 mln Q3 net loss

Overview

Minerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024
Company's Q3 operating expenses decreased due to lower R&D and G&A costs
Minerva secures $80 mln in financing for Phase 3 trial of roluperidone

Outlook

Minerva anticipates increased R&D and administrative expenses for Phase 3 trial and NDA resubmission
Company expects to have sufficient funds for Phase 3 study and potential US launch

Result Drivers

FINANCING - Minerva received $80 mln in private placement to fund Phase 3 trial of roluperidone
LOWER R&D EXPENSES - R&D expenses decreased due to lower costs for drug substance validation and consultant fees
LOWER G&A EXPENSES - G&A expenses fell due to reduced professional service fees and insurance costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.36
Q3 Net Income		-$2.74 mln
Q3 Income from Operations		-$2.84 mln
Q3 Operating Expenses		$2.84 mln

Press Release: ID:nGNXbBfpzw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581722627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581722627","market":"nz","top_or_hot":-1,"title":"Minerva Neurosciences reports $2.7 mln Q3 net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/NERV\">Minerva Neurosciences</a> reports $2.7 mln Q3 net loss</title></head><body><p><span>Overview</span></p><ul><li><p>Minerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024</p></li><li><p>Company's Q3 operating expenses decreased due to lower R&amp;D and G&amp;A costs</p></li><li><p>Minerva secures $80 mln in financing for Phase 3 trial of roluperidone</p></li></ul><p><span>Outlook</span></p><ul><li><p>Minerva anticipates increased R&amp;D and administrative expenses for Phase 3 trial and NDA resubmission</p></li><li><p>Company expects to have sufficient funds for Phase 3 study and potential US launch</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCING - Minerva received $80 mln in private placement to fund Phase 3 trial of roluperidone</p></li><li><p>LOWER R&amp;D EXPENSES - R&amp;D expenses decreased due to lower costs for drug substance validation and consultant fees</p></li><li><p>LOWER G&amp;A EXPENSES - G&amp;A expenses fell due to reduced professional service fees and insurance costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.36</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.74 mln</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$2.84 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$2.84 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNXbBfpzw</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Minerva Neurosciences reports $2.7 mln Q3 net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMinerva Neurosciences reports $2.7 mln Q3 net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 20:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/NERV\">Minerva Neurosciences</a> reports $2.7 mln Q3 net loss</title></head><body><p><span>Overview</span></p><ul><li><p>Minerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024</p></li><li><p>Company's Q3 operating expenses decreased due to lower R&amp;D and G&amp;A costs</p></li><li><p>Minerva secures $80 mln in financing for Phase 3 trial of roluperidone</p></li></ul><p><span>Outlook</span></p><ul><li><p>Minerva anticipates increased R&amp;D and administrative expenses for Phase 3 trial and NDA resubmission</p></li><li><p>Company expects to have sufficient funds for Phase 3 study and potential US launch</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCING - Minerva received $80 mln in private placement to fund Phase 3 trial of roluperidone</p></li><li><p>LOWER R&amp;D EXPENSES - R&amp;D expenses decreased due to lower costs for drug substance validation and consultant fees</p></li><li><p>LOWER G&amp;A EXPENSES - G&amp;A expenses fell due to reduced professional service fees and insurance costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.36</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.74 mln</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$2.84 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$2.84 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNXbBfpzw</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NERV","symbol_name":"Minerva Neurosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0NC:1","article_id":"2581722627","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581722627","pubTimestamp":1762346363,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Minerva Neurosciences reports $2.7 mln Q3 net lossOverviewMinerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024Company's Q3 operating expenses decreased due to lower R&D and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NERV":"Minerva Neurosciences","BK4139":"生物科技"},"translate_title":"Minerva Neurosciences报告第三季度净亏损270万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NERV":0.9},"content_text":"Minerva Neurosciences reports $2.7 mln Q3 net lossOverviewMinerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024Company's Q3 operating expenses decreased due to lower R&D and G&A costsMinerva secures $80 mln in financing for Phase 3 trial of roluperidoneOutlookMinerva anticipates increased R&D and administrative expenses for Phase 3 trial and NDA resubmissionCompany expects to have sufficient funds for Phase 3 study and potential US launchResult DriversFINANCING - Minerva received $80 mln in private placement to fund Phase 3 trial of roluperidoneLOWER R&D EXPENSES - R&D expenses decreased due to lower costs for drug substance validation and consultant feesLOWER G&A EXPENSES - G&A expenses fell due to reduced professional service fees and insurance costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.36Q3 Net Income-$2.74 mlnQ3 Income from Operations-$2.84 mlnQ3 Operating Expenses$2.84 mlnPress Release: ID:nGNXbBfpzwFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581722627","isCrawlerRequest":true}